Similar HRQOL With Gilteritinib vs Placebo in FLT3-ITD+ AML Post-HCT
February 23rd 2024Betty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.